Program of Research for the Optimization of a Supervised Patient Pathway for Expectant According to Risk in Obstetrics (PROSPERO)

February 12, 2019 updated by: Hospices Civils de Lyon
This French multicentre open-label randomized trial will test the hypothesis that a coordinated health circuit based on obstetric risks, backed up by an electronic patient care reporting information system will optimize the continuum of pregnancy care monitoring. The electronic patient care reporting information system will be shared between patients, private practice physicians/midwifes, hospital physicians/midwifes and supervised by a coordinating midwife.

Study Overview

Status

Completed

Conditions

Study Type

Interventional

Enrollment (Actual)

1532

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Bron, France, 69677
        • Hôpital Femme Mère Enfant
      • Lyon, France, 69002
        • Hospices Civils de Lyon

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • patients over the age of majority,
  • enrolled in one of the two maternity hospitals in the study before 12 weeks of amenorrhea (SA) and 6 days (j) of age,
  • affiliated to the National Health Insurance Fund of the country within the regional level health insurance
  • have an internet access

Exclusion Criteria:

  • illiterate patients,
  • non-French speakers,
  • under the age of majority,
  • refusing to participate,
  • without internet access,
  • followed by one of these maternity wards but delivering else where,
  • whose pregnancy ended in a miscarriage early or late (before 21 weeks of amenorrhea (SA) and 6 days (J) over).

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Placebo Comparator: control group
At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
Active Comparator: PROSPERO group (intervention group)

The intervention is carried out in 3 steps:

  1. At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.
  2. During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system
  3. The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Rate of patients'pathway approved as compliant in the intervention group compared to the control group.
Time Frame: at the end of pregnancy
Compliant patient pathways are those for which all actions (medical visits, examinations, …) recommended during pregnancy, according to the specific risk factors of each patient, will have been made.
at the end of pregnancy

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
rate of severe maternal morbidity and mortality as defined by the EPIdémiologie de la MOrbidité Maternelle Sévère (EPINOMS) project
Time Frame: From 22 completed weeks (154 days) of gestation to seven completed days after birth
From 22 completed weeks (154 days) of gestation to seven completed days after birth
rate of perinatal morbidity-mortality as defined by the Organization, Practices Evaluation in perinatal Network
Time Frame: From 22 completed weeks (154 days) of gestation to seven completed days after birth
From 22 completed weeks (154 days) of gestation to seven completed days after birth
completeness of all hospital medical records
Time Frame: the end of pregnancy (the date of delivery)
completeness of hospital medical records compared to electronic patient-reported outcome (ePRO).
the end of pregnancy (the date of delivery)
health care costs
Time Frame: one week from the date of delivery
Number of medical visits and hospitalization
one week from the date of delivery
health care costs
Time Frame: one week from the date of delivery
duration of medical visits and hospitalization
one week from the date of delivery
patients' satisfaction : Qualitative evaluation by interview
Time Frame: at the end of pregnancy
Qualitative evaluation of patients' satisfaction and adherence by interview and/or focus groups. Quantitative evaluation of patients' satisfaction and anxiety by the hospital anxiety and depression scale and other validated's patient satisfaction forms
at the end of pregnancy
patients' satisfaction : Quantitative evaluation by the hospital anxiety and depression scale
Time Frame: at the end of pregnancy
Quantitative evaluation of patients' satisfaction and anxiety by the hospital anxiety and depression scale
at the end of pregnancy
patients' satisfaction : Qualitative evaluation by interview
Time Frame: within one week from the date of delivery
Qualitative evaluation of patients' satisfaction and adherence by interview and/or focus groups.
within one week from the date of delivery
patients' satisfaction : Quantitative evaluation by the hospital anxiety and depression scale
Time Frame: within one week from the date of delivery
Quantitative evaluation of patients' satisfaction and anxiety by the hospital anxiety and depression scale and other validated's patient satisfaction forms
within one week from the date of delivery
types of delivery
Time Frame: within one week from the date of delivery
rate of vaginal delivery, instrumental extraction delivery, Caesarean delivery
within one week from the date of delivery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: René-Charles RUDIGOZ, Pr, Hospices Civils de Lyon

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 5, 2016

Primary Completion (Actual)

July 1, 2018

Study Completion (Actual)

July 1, 2018

Study Registration Dates

First Submitted

October 28, 2015

First Submitted That Met QC Criteria

October 29, 2015

First Posted (Estimate)

November 1, 2015

Study Record Updates

Last Update Posted (Actual)

February 15, 2019

Last Update Submitted That Met QC Criteria

February 12, 2019

Last Verified

February 1, 2019

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pregnancy

3
Subscribe